News & Events

From April 8th to 11th, the National Exhibition and Convention Center in Shanghai welcomed the annual global medical industry event —— the 91st China International Medical Equipment Fair (CMEF2025). As a barometer of the industry, this exhibition took 'Innovative Technology, Leading the Future with Intelligence' as its theme, attracting nearly 5,000 enterprises from more than 30 countries and regions to participate in the exhibition. Over 200,000 professional visitors came together to explore the frontiers of medical technology.  

The booth of Gendx Biotech has attracted widespread attention of the whole venue.

Suzhou Gendx Biotech Technology Co., Ltd. showcased its new-generation ERA Super Amplification Technology at Booth 7.1J02. With the core concept of 'Utmost Authenticity, Extreme Speed, and Ultimate Simplicity', it demonstrated the strength of Made-in-China intelligent manufacturing to the world and led the way in opening a new era of ten-minute POCT (Point-of-Care Testing) molecular diagnosis. The booth was bustling with people, and customers from both home and abroad kept coming. Customers from regions such as the Middle East, India, South Korea, and Europe have shown their recognition and love for our company's products, expressing a strong intention to cooperate. Some customers even urgently expressed their desire to visit our company.  

先达基因现场热图      

CMEF展会

At the exhibition, the Isothermal Nucleic Acid Amplification Analyzer GD-220, which has obtained the Class III Medical Device Certificate, successfully aroused the interest of domestic customers due to its technological innovation, the clinical application value of the detection of Mycoplasma pneumoniae, and its broad market prospects. More than 300 copies of promotional materials were snapped up. Many hospital experts and directors spoke highly of it. At the same time, they also put forward pertinent suggestions for the development of our company's products.

At the exhibition, another 'star product' of Gendx, the Isothermal Amplification Analyzer GCP-30, when paired with the GENECHIP, can achieve the remarkable feat of 'detecting 30 items at one time and generating results within 20 minutes', which also caught the attention of a large number of customers. Customers have shown unprecedented confidence in the ERA+ microfluidic technology, pointing out the way forward for Gendx.

After the COVID-19 pandemic, the risk of mixed infections of respiratory diseases (such as influenza + Mycoplasma + SARS-CoV-2) has increased, and the complexity of diagnosis and treatment has also risen. Early diagnosis and early treatment have become the common understanding of the public. Against this backdrop, Gendx has fully utilized the advantages of ERA technology to tackle the challenges in the detection of Mycoplasma pneumoniae. Moreover, on this basis, it is necessary to meet the needs of the development of the times, listen to customers' demands, and continuously update and improve the detection scenarios of pathogens in all scenarios, so that genetic technology can safeguard the public's health.

The outstanding performance at this exhibition not only has given our partners full confidence in future cooperation with Gendx, but also has strengthened Gendx's unwavering belief on the path of technological research and development. We will always adhere to the development of detection technologies with the core features of being rapid, accurate, and portable. We are committed to transforming cutting-edge genetic technologies into tangible practical values, enabling advanced detection capabilities to break through the limitations of scenarios, and truly serving public health. We will practice our original aspiration and responsibility of 'making genetic technology inclusive and beneficial to all' with the warmth of technology.